SB
RANI icon

Samsara BioCapital’s Rani Therapeutics RANI Stock Holding History

Samsara BioCapital’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.88M Buy
10,369,159
+1,869,159
+22% +$1.66M 0.65% 17
2026
Q1 		$6.25M Hold
8,500,000
– – 0.61% 19
2025
Q4 		$11.5M Buy
+8,500,000
New +$12.8M 1.18% 13

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Samsara BioCapital's RANI Position: Q2 2026 in Review

Samsara BioCapital increased its Rani Therapeutics (RANI) stake by 22% in Q2 2026, buying an estimated $1.66M and bringing the position to 10,369,159 shares worth $7.88M. The position accounts for 0.65% of the portfolio, ranked #17.

Samsara BioCapital first reported a position in RANI in Q4 2025 and has held it in 3 quarters since. The position peaked at $11.5M in Q4 2025. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Samsara BioCapital held 10,369,159 shares of Rani Therapeutics worth $7.88M as of Q2 2026.
  • Samsara BioCapital bought 1,869,159 Rani Therapeutics shares in Q2 2026, an estimated $1.66M.
  • Rani Therapeutics made up 0.65% of Samsara BioCapital's portfolio in Q2 2026, its #17 holding.
  • Samsara BioCapital first reported a position in Rani Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Samsara BioCapital's Rani Therapeutics position peaked at $11.5M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Samsara BioCapital's 13F filing for Q2 2026, filed 14 Aug 2026.